EVANSTON, Ill.--(BUSINESS WIRE)--Minute Molecular Diagnostics today announced that the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for its rapid DASH ...
The FDA has issued its first emergency use authorization for a COVID-19 molecular diagnostic test that does not require a prescription and can be used at home. Developed by Cue Health, the Cue ...
The Canada Point of Care Molecular Diagnostics Market, valued at USD 350 million in 2024, is projected to reach USD 560 ...
Streamlining Respiratory Virus Testing with Molecular Diagnostics: Impact on patients and laboratory
Join us for an insightful webinar on the critical role of molecular diagnostic testing for respiratory viruses during flu season. This session will explore the importance of accurate and timely ...
Home diagnostics company Cue Health announced its received FDA de novo authorization for its at-home COVID-19 test, dubbed the Cue COVID-19 Molecular Test. The Cue COVID-19 Molecular Test detects ...
2025 update: This federal program has ended and free tests are not current available from the government website. Federal health officials have justified the millions they have spent on device ...
3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...
New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results